Aram J. Krauson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Aram J. Krauson has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- William C. Wimley
Tulane University School of Medicine
8 shared publications Jing He
Department of Biochemistry SL43 Tulane University School of Medicine New Orleans LA 70112
4 shared publications- Marcelo D. Carattino
Renal-Electrolyte Division, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
3 shared publications - Dadi Gao
Center for Genomic Medicine and Department of Neurology, Massachusetts General Hospital, and Harvard Medical School, Boston
2 shared publications Emily M. Logan
Center for Genomic Medicine, Massachusetts General Hospital Research Institute, Boston, MA
2 shared publications- James R. Stone
Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
2 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 27 September 2023
- Published by Springer Nature in npj Vaccines
- Vol. 8 (1) , 1-8
Duration of SARS-CoV-2 mRNA vaccine persistence and factors associated with cardiac involvement in recently vaccinated patients
At the start of the COVID-19 pandemic, the BNT162b2 (BioNTech-Pfizer) and mRNA-1273 (Moderna) mRNA vaccines were expediently designed and mass produced. Both vaccines produce the full-length SARS-CoV-2 spike protein for gain of immunity and have greatly reduced mortality and morbidity from SARS-CoV-2 infection. The distribution and duration of SARS-CoV-2 mRNA vaccine persistence in human tissues is unclear. Here, we developed specific RT-qPCR-based assays to detect each mRNA vaccine and screened lymph nodes, liver, spleen, and myocardium from recently vaccinated deceased patients. Vaccine was detected in the axillary lymph nodes in the majority of patients dying within 30 days of vaccination, but not in patients dying more than 30 days from vaccination. Vaccine was not detected in the mediastinal lymph nodes, spleen, or liver. Vaccine was detected in the myocardium in a subset of patients vaccinated within 30 days of death. Cardiac ventricles in which vaccine was detected had healing myocardial injury at the time of vaccination and had more myocardial macrophages than the cardiac ventricles in which vaccine was not detected. These results suggest that SARS-CoV-2 mRNA vaccines routinely persist up to 30 days from vaccination and can be detected in the heart.
- 27 September 2023
- Published by Springer Nature in npj Vaccines
- Vol. 8 (1) , 1-8
Top Cited PapersOpen AccessDuration of SARS-CoV-2 mRNA vaccine persistence and factors associated with cardiac involvement in recently vaccinated patients
At the start of the COVID-19 pandemic, the BNT162b2 (BioNTech-Pfizer) and mRNA-1273 (Moderna) mRNA vaccines were expediently designed and mass produced. Both vaccines produce the full-length SARS-CoV-2 spike protein for gain of immunity and have greatly reduced mortality and morbidity from SARS-CoV-2 infection. The distribution and duration of SARS-CoV-2 mRNA vaccine persistence in human tissues is unclear. Here, we developed specific RT-qPCR-based assays to detect each mRNA vaccine and screened lymph nodes, liver, spleen, and myocardium from recently vaccinated deceased patients. Vaccine was detected in the axillary lymph nodes in the majority of patients dying within 30 days of vaccination, but not in patients dying more than 30 days from vaccination. Vaccine was not detected in the mediastinal lymph nodes, spleen, or liver. Vaccine was detected in the myocardium in a subset of patients vaccinated within 30 days of death. Cardiac ventricles in which vaccine was detected had healing myocardial injury at the time of vaccination and had more myocardial macrophages than the cardiac ventricles in which vaccine was not detected. These results suggest that SARS-CoV-2 mRNA vaccines routinely persist up to 30 days from vaccination and can be detected in the heart.
- Open Access
- 9 December 2021
- Published by Elsevier in Journal of Genetics and Genomics
- Vol. 49 (7) , 654-665
Developmental regulation of neuronal gene expression by Elongator complex protein 1 dosage
- 9 December 2021
- Published by Elsevier in Journal of Genetics and Genomics
- Vol. 49 (7) , 654-665
Open AccessDevelopmental regulation of neuronal gene expression by Elongator complex protein 1 dosage
- 1 July 2021
- Published by Elsevier in Laboratory Investigation
- Vol. 34 (7) , 1345-1357
Factors associated with myocardial SARS-CoV-2 infection, myocarditis, and cardiac inflammation in patients with COVID-19
- 1 July 2021
- Published by Elsevier in Laboratory Investigation
- Vol. 34 (7) , 1345-1357
Factors associated with myocardial SARS-CoV-2 infection, myocarditis, and cardiac inflammation in patients with COVID-19
- Open Access
- 7 June 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-15
A deep learning approach to identify gene targets of a therapeutic for human splicing disorders
Pre-mRNA splicing is a key controller of human gene expression. Disturbances in splicing due to mutation lead to dysregulated protein expression and contribute to a substantial fraction of human disease. Several classes of splicing modulator compounds (SMCs) have been recently identified and establish that pre-mRNA splicing represents a target for therapy. We describe herein the identification of BPN-15477, a SMC that restores correct splicing of ELP1 exon 20. Using transcriptome sequencing from treated fibroblast cells and a machine learning approach, we identify BPN-15477 responsive sequence signatures. We then leverage this model to discover 155 human disease genes harboring ClinVar mutations predicted to alter pre-mRNA splicing as targets for BPN-15477. Splicing assays confirm successful correction of splicing defects caused by mutations in CFTR, LIPA, MLH1 and MAPT. Subsequent validations in two disease-relevant cellular models demonstrate that BPN-15477 increases functional protein, confirming the clinical potential of our predictions.
- 7 June 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-15
Open AccessA deep learning approach to identify gene targets of a therapeutic for human splicing disorders
Pre-mRNA splicing is a key controller of human gene expression. Disturbances in splicing due to mutation lead to dysregulated protein expression and contribute to a substantial fraction of human disease. Several classes of splicing modulator compounds (SMCs) have been recently identified and establish that pre-mRNA splicing represents a target for therapy. We describe herein the identification of BPN-15477, a SMC that restores correct splicing of ELP1 exon 20. Using transcriptome sequencing from treated fibroblast cells and a machine learning approach, we identify BPN-15477 responsive sequence signatures. We then leverage this model to discover 155 human disease genes harboring ClinVar mutations predicted to alter pre-mRNA splicing as targets for BPN-15477. Splicing assays confirm successful correction of splicing defects caused by mutations in CFTR, LIPA, MLH1 and MAPT. Subsequent validations in two disease-relevant cellular models demonstrate that BPN-15477 increases functional protein, confirming the clinical potential of our predictions.
- Open Access
Proximal and Distal Nephron-specific Adaptation to Furosemide
Furosemide, a widely prescribed diuretic for edema-forming states, inhibits sodium reabsorption in the thick ascending limb of the nephron. Tubular adaptation to diuretics has been observed, but the range of mechanisms along the nephron has not been fully explored. Using morphometry, we show that furosemide induces renal tubular epithelial hyperplasia selectively in distal nephron segments. By comparison, we find progressive cellular hypertrophy in proximal and distal nephron segments. We next utilize single cell RNA sequencing of vehicle- and furosemide-treated mice to define potential mechanisms of diuretic resistance. Consistent with distal tubular cell hyperplasia, we detect a net increase in DCT cell number and Birc5 , an anti-apoptotic and pro-growth gene, in a subset of DCT cells, as the most prominently up-regulated gene across the nephron. We also map a gradient of cell-specific transcriptional changes congruent with enhanced distal sodium transport. Furosemide stimulates expression of the mitogen IGF-1. Thus, we developed a mouse model of inducible deletion of renal tubular IGF-1 receptor and show reduced kidney growth and proximal, but not distal, tubular hypertrophy by furosemide. Moreover, genes that promote enhanced bioavailability of IGF-1 including Igfbp1 and Igfbp5 are significantly and differentially expressed in proximal tubular segments and correspond to IGF-1R-dependent hypertrophy. In contrast, downstream PI3-kinase signaling genes including Pdk1, Akt1, Foxo3, FKBP4, Eif2BP4 , and Spp1 are significantly and differentially expressed in distal nephron segments and correspond to IGF-1R-independent hypertrophy. These findings highlight novel mechanisms of tubular remodeling and diuretic resistance, provide a repository of transcriptional responses to a common drug, and expand the implications of long-term loop diuretic use for human disease.
Open AccessProximal and Distal Nephron-specific Adaptation to Furosemide
Furosemide, a widely prescribed diuretic for edema-forming states, inhibits sodium reabsorption in the thick ascending limb of the nephron. Tubular adaptation to diuretics has been observed, but the range of mechanisms along the nephron has not been fully explored. Using morphometry, we show that furosemide induces renal tubular epithelial hyperplasia selectively in distal nephron segments. By comparison, we find progressive cellular hypertrophy in proximal and distal nephron segments. We next utilize single cell RNA sequencing of vehicle- and furosemide-treated mice to define potential mechanisms of diuretic resistance. Consistent with distal tubular cell hyperplasia, we detect a net increase in DCT cell number and Birc5 , an anti-apoptotic and pro-growth gene, in a subset of DCT cells, as the most prominently up-regulated gene across the nephron. We also map a gradient of cell-specific transcriptional changes congruent with enhanced distal sodium transport. Furosemide stimulates expression of the mitogen IGF-1. Thus, we developed a mouse model of inducible deletion of renal tubular IGF-1 receptor and show reduced kidney growth and proximal, but not distal, tubular hypertrophy by furosemide. Moreover, genes that promote enhanced bioavailability of IGF-1 including Igfbp1 and Igfbp5 are significantly and differentially expressed in proximal tubular segments and correspond to IGF-1R-dependent hypertrophy. In contrast, downstream PI3-kinase signaling genes including Pdk1, Akt1, Foxo3, FKBP4, Eif2BP4 , and Spp1 are significantly and differentially expressed in distal nephron segments and correspond to IGF-1R-independent hypertrophy. These findings highlight novel mechanisms of tubular remodeling and diuretic resistance, provide a repository of transcriptional responses to a common drug, and expand the implications of long-term loop diuretic use for human disease.
- Open Access
- 21 May 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (5) , e0196894
Molecular basis of inhibition of acid sensing ion channel 1A by diminazene
Acid-sensing ion channels (ASICs) are trimeric proton-gated cation permeable ion channels expressed primarily in neurons. Here we employed site-directed mutagenesis and electrophysiology to investigate the mechanism of inhibition of ASIC1a by diminazene. This compound inhibits mouse ASIC1a with a half-maximal inhibitory concentration (IC50) of 2.4 μM. At first, we examined whether neutralizing mutations of Glu79 and Glu416 alter diminazene block. These residues form a hexagonal array in the lower palm domain that was previously shown to contribute to pore opening in response to extracellular acidification. Significantly, single Gln substitutions at positions 79 and 416 in ASIC1a reduced diminazene apparent affinity by 6–7 fold. This result suggests that diminazene inhibits ASIC1a in part by limiting conformational rearrangement in the lower palm domain. Because diminazene is charged at physiological pHs, we assessed whether it inhibits ASIC1a by blocking the ion channel pore. Consistent with the notion that diminazene binds to a site within the membrane electric field, diminazene block showed a strong dependence with the membrane potential. Moreover, a Gly to Ala mutation at position 438, in the ion conduction pathway of ASIC1a, increased diminazene IC50 by one order of magnitude and eliminated the voltage dependence of block. Taken together, our results indicate that the inhibition of ASIC1a by diminazene involves both allosteric modulation and blocking of ion flow through the conduction pathway. Our findings provide a foundation for the development of more selective and potent ASIC pore blockers.
- 21 May 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (5) , e0196894
Open AccessMolecular basis of inhibition of acid sensing ion channel 1A by diminazene
Acid-sensing ion channels (ASICs) are trimeric proton-gated cation permeable ion channels expressed primarily in neurons. Here we employed site-directed mutagenesis and electrophysiology to investigate the mechanism of inhibition of ASIC1a by diminazene. This compound inhibits mouse ASIC1a with a half-maximal inhibitory concentration (IC50) of 2.4 μM. At first, we examined whether neutralizing mutations of Glu79 and Glu416 alter diminazene block. These residues form a hexagonal array in the lower palm domain that was previously shown to contribute to pore opening in response to extracellular acidification. Significantly, single Gln substitutions at positions 79 and 416 in ASIC1a reduced diminazene apparent affinity by 6–7 fold. This result suggests that diminazene inhibits ASIC1a in part by limiting conformational rearrangement in the lower palm domain. Because diminazene is charged at physiological pHs, we assessed whether it inhibits ASIC1a by blocking the ion channel pore. Consistent with the notion that diminazene binds to a site within the membrane electric field, diminazene block showed a strong dependence with the membrane potential. Moreover, a Gly to Ala mutation at position 438, in the ion conduction pathway of ASIC1a, increased diminazene IC50 by one order of magnitude and eliminated the voltage dependence of block. Taken together, our results indicate that the inhibition of ASIC1a by diminazene involves both allosteric modulation and blocking of ion flow through the conduction pathway. Our findings provide a foundation for the development of more selective and potent ASIC pore blockers.
- Open Access
- 1 May 2016
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 291 (21) , 11407-11419
The Thumb Domain Mediates Acid-sensing Ion Channel Desensitization
- 1 May 2016
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 291 (21) , 11407-11419
Open AccessThe Thumb Domain Mediates Acid-sensing Ion Channel Desensitization
- Open Access
- 18 December 2015
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 137 (51) , 16144-16152
Conformational Fine-Tuning of Pore-Forming Peptide Potency and Selectivity
To better understand the sequence-structure-function relationships that control the activity and selectivity of membrane permeabilizing peptides, we screened a peptide library, based on the archetypal pore-former melittin, for loss-of-function variants. This was accomplished by assaying library members for failure to cause leakage of entrapped contents from synthetic lipid vesicles at a peptide to lipid ratio (P:L) of 1:20, ten-fold higher than the concentration at which melittin efficiently permeabilizes the same vesicles. Surprisingly, about one third of the library members are inactive under these conditions. In the negative peptides, two changes of hydrophobic residues to glycine were especially abundant. We show that loss-of-function activity can be completely recapitulated by a single residue change of the leucine at position 16 to glycine. Unlike the potently cytolytic melittin, the loss-of-function peptides, including the single site variant, are essentially inactive against phosphatidylcholine ve...
- 18 December 2015
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 137 (51) , 16144-16152
Open AccessConformational Fine-Tuning of Pore-Forming Peptide Potency and Selectivity
To better understand the sequence-structure-function relationships that control the activity and selectivity of membrane permeabilizing peptides, we screened a peptide library, based on the archetypal pore-former melittin, for loss-of-function variants. This was accomplished by assaying library members for failure to cause leakage of entrapped contents from synthetic lipid vesicles at a peptide to lipid ratio (P:L) of 1:20, ten-fold higher than the concentration at which melittin efficiently permeabilizes the same vesicles. Surprisingly, about one third of the library members are inactive under these conditions. In the negative peptides, two changes of hydrophobic residues to glycine were especially abundant. We show that loss-of-function activity can be completely recapitulated by a single residue change of the leucine at position 16 to glycine. Unlike the potently cytolytic melittin, the loss-of-function peptides, including the single site variant, are essentially inactive against phosphatidylcholine ve...
- 1 January 2015
- Published by Elsevier in Biophysical Journal
- Vol. 108 (2) , 288a
Functional Coupling between the Finger and Thumb Domains of ASIC1A
- 1 January 2015
- Published by Elsevier in Biophysical Journal
- Vol. 108 (2) , 288a
Functional Coupling between the Finger and Thumb Domains of ASIC1A
- 17 January 2014
- Published by Wiley in Peptide Science
- Vol. 102 (1) , 1-6
Toward the de novo design of antimicrobial peptides: Lack of correlation between peptide permeabilization of lipid vesicles and antimicrobial, cytolytic, or cytotoxic activity in living cells
We previously performed a lipid vesicle‐based, high‐throughput screen on a 26‐residue combinatorial peptide library that was designed de novo to yield membrane‐permeabilizing peptides that fold into β‐sheets. The most active and soluble library members that were identified permeabilized lipid vesicles detectably, but not with high potency. Nonetheless, they were broad‐spectrum, membrane‐permeabilizing antibiotics with minimum sterilizing activity at low µM concentrations. In an expansion of that work, we recently performed an iterative screen in which an active consensus sequence from that first‐generation library was used as a template to design a second‐generation library which was then screened against lipid vesicles at very high stringency. Compared to the consensus sequence from the first library, the most active second‐generation peptides are highly potent, equilibrium pore‐formers in synthetic lipid vesicles. Here, we use these first‐ and second‐generation families of peptides to test the hypothesis that a large increase in potency in bacteria‐like lipid vesicles will correlate with a large improvement in antimicrobial activity. The results do not support the hypothesis. Despite a 20‐fold increase in potency against bacteria‐like lipid vesicles, the second‐generation peptides are only slightly more active against bacteria, and at the same time, are also more toxic against mammalian cells. The results suggest that a “pipeline” strategy toward the optimization of antimicrobial peptides could begin with a vesicle‐based screen for identifying families with broad‐spectrum activity, but will also need to include screening or optimization steps that are done under conditions that are more directly relevant to possible therapeutic applications. © 2013 Wiley Periodicals, Inc. Biopolymers (Pept Sci) 102: 1–6, 2014.
- 17 January 2014
- Published by Wiley in Peptide Science
- Vol. 102 (1) , 1-6
Toward the de novo design of antimicrobial peptides: Lack of correlation between peptide permeabilization of lipid vesicles and antimicrobial, cytolytic, or cytotoxic activity in living cells
We previously performed a lipid vesicle‐based, high‐throughput screen on a 26‐residue combinatorial peptide library that was designed de novo to yield membrane‐permeabilizing peptides that fold into β‐sheets. The most active and soluble library members that were identified permeabilized lipid vesicles detectably, but not with high potency. Nonetheless, they were broad‐spectrum, membrane‐permeabilizing antibiotics with minimum sterilizing activity at low µM concentrations. In an expansion of that work, we recently performed an iterative screen in which an active consensus sequence from that first‐generation library was used as a template to design a second‐generation library which was then screened against lipid vesicles at very high stringency. Compared to the consensus sequence from the first library, the most active second‐generation peptides are highly potent, equilibrium pore‐formers in synthetic lipid vesicles. Here, we use these first‐ and second‐generation families of peptides to test the hypothesis that a large increase in potency in bacteria‐like lipid vesicles will correlate with a large improvement in antimicrobial activity. The results do not support the hypothesis. Despite a 20‐fold increase in potency against bacteria‐like lipid vesicles, the second‐generation peptides are only slightly more active against bacteria, and at the same time, are also more toxic against mammalian cells. The results suggest that a “pipeline” strategy toward the optimization of antimicrobial peptides could begin with a vesicle‐based screen for identifying families with broad‐spectrum activity, but will also need to include screening or optimization steps that are done under conditions that are more directly relevant to possible therapeutic applications. © 2013 Wiley Periodicals, Inc. Biopolymers (Pept Sci) 102: 1–6, 2014.